In response to the global race to combat the Covid-19 pandemic, the World Health Organization embraced a proposal Friday to create a voluntary pool to collect patent rights, regulatory test data, and other information that could be shared for developing drugs, vaccines, and diagnostics.

The notion was raised several weeks ago by Costa Rican officials amid mounting concern that some Covid-19 medical products may not be accessible for poorer populations. By establishing a voluntary mechanism under the auspices of the WHO, the goal is to establish a pathway that will attract numerous governments, as well as industry, universities and nonprofit organizations.

“We want to create a repository,” said Costa Rican President Carlos Alvarado Quesada in a media briefing Friday that WHO leaders described as a “pre-launch.” He added that “the idea is to make available for everybody around the world the different advances and innovations and put those into service at lower costs to protect people… This is a call for solidarity and a call for action” to defeat the novel coronavirus

advertisement

A formal launch is scheduled for May 29, as negotiations continue with various countries, according to Mariangela Simao, the WHO Assistant Director General for Access to Medicines, Vaccines and Pharmaceuticals. She predicted that, “in two weeks’ time, member states from all regions” will agree to participate, although she did not indicate how many countries have so far signed on.

The World Health Assembly, which governs the WHO, is considering a resolution that, in part, embraces a voluntary pool in hopes of ensuring that less-developed countries can navigate patent rights for Covid-19 medical products. The WHO would be responsible for creating a framework for the pool. The resolution was submitted by the European Union, although the U.S. has pushed back on certain provisions.

advertisement

To what extent the proposal will take off remains unclear. The Costa Rican initiative is, after all, voluntary. As WHO Director General Tedros Adhanom Ghebreyesus carefully noted, there is a “a general understanding” that countries that agree to join the pool will “move forward. All countries that sign the resolution are expected to implement it.”

Meanwhile, the WHO late last month announced a broader effort — called the Access to Covid-19 Tools Accelerator — and a long list of countries, industry groups, and non-governmental organizations agreed to work together to develop and produce new drugs, vaccines and diagnostics. Ensuring equitable access to any resulting medical products, however, is another matter.

The pandemic may pose the same health and economic challenges to every country, but there are unanswered questions about manufacturer returns on investments, production capacities, and the logistics of distribution, among other things. To a great extent, these sorts of problems emerged before as poor countries have tried to fend off various infectious diseases, but on smaller, regional scales.

The issue is more perplexing now, though, as what might be called pandemic chauvinism emerges. In the U.S., for instance, the Trump administration reportedly tried to persuade CureVac, a German vaccine maker, to move research to the U.S. The disclosure triggered uproar in Germany and raised concerns elsewhere that the wealthier nations might try to get first crack at useful drugs or vaccines.

A similar episode erupted this week when Sanofi chief executive officer Paul Hudson caused outrage in France, where the drug maker is headquartered, when he disclosed that the U.S. would get priority access to any Covid-19 vaccine. Why? The U.S. government is funding some of its vaccine research. French officials reacted with fury and called for a meeting next week with Sanofi officials.

The U.S., in particular, remains a wild card. Angered over the spread of the virus from China and the role the WHO played in alerting the world to the pandemic, the Trump administration has moved to withhold its funding of the global agency. The U.S. was also conspicuously absent when the WHO announced its Access to Covid-19 Tools Accelerator.

Asked if he expected the U.S. to consider joining the voluntary pool, Tedros offered a sobering, but realistic response: “I cannot answer that question. I think you better ask the president.”

  • What a great idea! Give IP to the guys who created the need by groveling at China’s feet. Great irony would be if Taiwan created the best vaccine candidate- Ooopps; never mind. Taiwan doesn’t exist.

    Next!

  • WHO and Tedros, in alignment with China, withheld critical information about CoViD-19 when it first emerged in China. This allowed time for China to stockpile PPE and ventilators. WHO and Tedros were complicit in allowing the Chinese people in Wuhan to fly to other parts of the world, but not to other areas in China such as Beijing, thereby creating a pandemic. Why would any country trust intellectual property, vaccines, diagnostics, and therapeutics provided to WHO to be shared with any other country except China?

  • A country withholding funding to a global agency effectively removes itself from the players list of that agency. So to the WHO it does not matter what the US thinks on pooling intellectual property – or anything else. The US administration’s decision does not seem to lead to a win-win situation.

  • While drug and vaccine developers are working on tools to prevent and treat Covid- 19, here is a question the rest of us should consider: Who will get access to those new products? Experience of previous pandemics shows that unless deliberate steps are taken, universal access will not happen. The most vulnerable people will be left out in the cold.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy